Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Liabilities and Shareholders Equity (2016 - 2025)

Adma Biologics' Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $624.2 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 27.74% year-over-year to $624.2 million; the TTM value through Dec 2025 reached $2.3 billion, up 40.79%, while the annual FY2025 figure was $624.2 million, 27.74% up from the prior year.
  • Liabilities and Shareholders Equity reached $624.2 million in Q4 2025 per ADMA's latest filing, up from $568.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $624.2 million in Q4 2025 to a low of $232.8 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $373.4 million, with a median of $345.7 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: fell 5.53% in 2023, then soared 48.45% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $276.3 million in 2021, then rose by 26.14% to $348.5 million in 2022, then dropped by 5.53% to $329.2 million in 2023, then soared by 48.45% to $488.7 million in 2024, then increased by 27.74% to $624.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Liabilities and Shareholders Equity are $624.2 million (Q4 2025), $568.7 million (Q3 2025), and $558.4 million (Q2 2025).